HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.

AbstractINTRODUCTION: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). METHODS: Pretreatment fine-needle aspiration specimens from 45 patients with HER-2-overexpressing stage II to IIIA breast cancer were subjected to transcriptional profiling and examined for differential expression of various genes and gene sets. The primary endpoint for tumor response was pathologic complete response (pCR). Correlations between pCR and gene expression were sought. RESULTS: The overall pCR rate was 64%. Age, nuclear grade, tumor size, nodal status, quantitative expression of estrogen and HER-2 receptor mRNA, and HER-2 gene copy number showed no correlation with pCR. Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. CONCLUSION: CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer.
AuthorsFrancisco J Esteva, Jing Wang, Feng Lin, Jaime A Mejia, Kai Yan, Kadri Altundag, Vicente Valero, Aman U Buzdar, Gabriel N Hortobagyi, W Fraser Symmans, Lajos Pusztai (Affiliation: Department of Breast Medical Oncology, Unit 1354, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. festeva at mdanderson.org)
JournalBreast cancer research : BCR (Breast Cancer Res) Vol. 9 Issue 6 Pg. R87 ( 2007) ISSN: 1465-542X [Electronic] England
PMID18086299 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD40
  • FEC protocol
  • RNA, Messenger
  • Tumor Markers, Biological
  • trastuzumab
  • Paclitaxel
  • Cyclophosphamide
  • Fluorouracil
  • Epirubicin
  • ERBB2 protein, human
  • Receptor, erbB-2
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (administration & dosage)
  • Antigens, CD40 (metabolism)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Biopsy, Fine-Needle
  • Breast Neoplasms (drug therapy, immunology, metabolism, pathology, surgery)
  • Cyclophosphamide (administration & dosage)
  • Epirubicin (administration & dosage)
  • Female
  • Fluorouracil (administration & dosage)
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mastectomy (methods)
  • Mastectomy, Modified Radical
  • Mastectomy, Segmental
  • Middle Aged
  • Neoadjuvant Therapy (methods)
  • Neoplasm Staging
  • Neoplasm, Residual
  • Paclitaxel (administration & dosage)
  • Predictive Value of Tests
  • RNA, Messenger (metabolism)
  • Receptor, erbB-2 (genetics, metabolism)
  • Signal Transduction
  • Transcription, Genetic
  • Treatment Outcome
  • Tumor Markers, Biological (metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD